Beasley, Allen, Crow, Methvin, Portis & Miles, P.C.

The Food and Drug Administration (FDA) is expected to issue a warming to doctors about an increased risk of the recurrence of breast cancer with patients taking both the breast cancer drug tamoxifen and select antidepressants, according to a study released last week at the American Society of Clinical Oncology’s annual meeting.

Read the rest of this entry »